The role of Immunotherapy by using NK cell therapy and Interleukin therapy in COVID-19

Nastaran Nikkhou ©, Parvaneh Farzaneh

The role of Immunotherapy by using NK cell therapy and Interleukin therapy in COVID-19

کد: G-08473

نویسندگان: Nastaran Nikkhou ©, Parvaneh Farzaneh

زمان بندی: زمان بندی نشده!

برچسب: ایمنی شناسی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Vaccination suitable solution for controlling the coronavirus disease (COVID-19) pandemic, but still there are some challenges in COVID-19 vaccination. Also, another medicinal option is Immunotherapy. Restoration of NK cell effector processes has the potential to correct the temperate immune balance required to effectively overcome SARS-CoV-2 infection. transfer of NK or CAR-NK cells with useful cytolytic potentials and the lowest capacity of cytokine-release to severe COVID-19 patients may provide an efficacious treatment mainly in cases suffering from cytokine storms.


Interleukins (ILs) 2, 12, 15, and 18 released by targets infected with the virus or active antigen-presenting cells can modulate NK cell function while increasing survival, proliferation, cytotoxicity, and cytokine production. IL-12 increases the production and secretion of IFN-γ by NK cells while IL-15 induces NK proliferation. Interleukin treatment can improve the effective function of NK cells. Given the importance of IL-15 signaling and NK cell function, researchers have created an "alternative" to IL-15, which is IL-15: IL-15R heterodimers that have better stability and bioactivity than IL-15 monomers. They have inside the body. Interleukin-6 (IL-6) is also a prognostic marker for COVID-19 infection, and tocilizumab blocks its receptors, the drug of choice for COVID-19 infection.


the supplementation of IL-2 and IL-15 supplies more NK cell maturing (CD56dim phenotype) with an applicable cytolytic effect. with the technologies available to create chimeric antigen receptor (CAR)-NK cells, it is nowadays too possible to design specific cell lines expressing any receptor. However, because these interleukins also act as pro-inflammatory cytokines, their therapeutic use should be associated with severe alert to control the worsening of COVID-19 patient's inflammatory conditions because of expanded levels of IL-15 also chronic pulmonary inflammatory diseases, and Middle East respiratory syndrome coronavirus (MERS- CoV) infection.


Immunotherapy has a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Given the significance of maintaining the innate immune system, particularly the function of NK cells to halt cytokine storms, be effective in preventing either acute diseases of COVID-19 or in the cure of severe conditions of this disease. appears that if the cytokine therapy is successful, their use in the cure of COVID-19 patients can be beneficial than NK cell therapies.


Immunotherapy; NK cell therapy; Interleukin therapy; COVID-19; Vaccine

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.